The Problem with Owning Blue-Chip Stocks Now

Promised Land

The Problem with Owning Blue-Chip Stocks Now

Shares of big, high-quality companies may win in the long run, but small and mid-sized companies offer better value for the next few months.

Since 2009, I've been hearing stock-market pundits say, "Buy quality, buy quality, buy quality." Voices whisper in my ear: "Buy J&J, buy Microsoft, buy Pfizer, buy Wal-Mart. Please buy J&J. Please, for heaven's sake, won't someone buy J&J?" Some of the sharpest investors on the planet, including Warren Buffett and Jeremy Grantham, of GMO, say that blue-chip stocks are dirt-cheap compared with the rest of the market.

Nonetheless, small caps, mid caps, cyclicals, gold stocks and companies that barely survived near-death experiences have all thrashed blue chips since the market bottomed in March 2009. The trend was evident in 2010. For the year, Standard & Poor's 500-stock index, which is dominated by large companies, returned 15.1%. But the S&P MidCap 400 index and the small-company Russell 2000 each gained 27%. Such prominent blue chips as Abbott Labs, Cisco Systems, Hewlett-Packard, Microsoft, Pfizer and, yes, Johnson & Johnson all fell in 2010.

Sponsored Content

Not Quite Yet

Jeremy Grantham has said that it is "almost a certain bet" that blue chips will outperform lower-quality stocks over the longer term. Quite possibly so -- but I'm not making that bet on a big scale just yet. Over the intermediate term -- the next three to six months -- I'm finding much more value in small caps and mid caps.

Now mind you, I have owned Cisco, Intel, J&J and some other true blues over the past 18 months. But I sold all of them, either because something seemed to be going wrong at the company (are there any products that J&J hasn't recalled?) or because I believed better opportunities beckoned elsewhere.


One of the big problems with owning blue chips now is that we're in the wrong part of the economic cycle for them. "In a recovering economy," says a well-known large-cap fund manager, "people want to invest in companies more geared to expansion." And with economic growth likely to accelerate in 2011, many investors see little reason to abandon this view.

Cleve Rueckert, a research associate at Birinyi Associates, offers an interesting perspective. His firm looks at which stocks money is flowing into and out of to determine what to own. As a result, Birinyi's top holdings include such novas as Apple, Chipotle Mexican Grill and Netflix. Such stocks "are good until they're not," Rueckert says. He notes, too, that the stock market has changed considerably over the past ten years: "A lot of buy-and-hold investors have been scared away. Now people want instant gratification."

I don't invest the way Birinyi does, but I currently have only 20% of my fund in those lagging blue chips. As I was writing this column, I decided to repurchase Microsoft (symbol MSFT) and Pfizer (PFE), but that may be it for a while. I believe in the long-term case for blue chips, but, as an investor, I'm taking Saint Augustine's approach: "Give me chastity and continence, but not yet."

On the other hand, Don Yacktman, the star manager of the Yacktman Fund, makes investment "chastity" look positively sexy. Even with Yacktman's focus on quality stocks, his fund has clobbered the S&P 500 by an average of 11 percentage points per year over the past decade.


And he's now stressing quality more than ever. "I've rarely seen quality so inexpensive," he says. His top five holdings are PepsiCo, News Corp., Coca-Cola, Microsoft and Pfizer. His fund's 12.6% return in 2010 trailed the market slightly, but Yacktman is unperturbed. "We have a ten-year horizon," he says.

What about the obvious problems besetting some blue chips? "They're temporary," he says, with an aplomb I can only envy. I know he's right. For the truly long-term investor, this is a great time to load up on high-quality stocks. As for the hedge-fund manager in me, well, I promise to load up soon -- just not quite yet.

Columnist Andrew Feinberg writes about the choices and challenges facing individual investors.